E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/26/2006 in the Prospect News Biotech Daily.

PRA's second-quarter service revenue down at $70.1 million

By Lisa Kerner

Charlotte, N.C., July 26 - PRA International Inc. said for the three-month period ended June 30 it generated service revenue of $70.1 million, down from the $76.0 million reported in the second quarter of 2005.

The company's service revenue for the six-month period ended June 30 also fell to $139.3 million from $149.6 million in the first six months of 2005.

Second-quarter income from operations was $7.0 million, a decrease from $13.7 million in the same quarter in 2005.

Income from operations in the first six months 2006 was $15.6 million, down from the $24.9 million a year ago.

PRA net income for the quarter was $6.8 million, or $0.28 per diluted share, down from net income of $8.5 million, or $0.35 per diluted share, for the second-quarter 2005.

The company's net income for the first six months fell to $12.9 million, or $0.53 per diluted share, from $15.5 million, or $0.63 per diluted share, a year ago.

The company's second-quarter 2006 cash flow from operations climbed to $22.2 million from $8.6 million in the year-ago quarter.

Cash flow from operations for the first half of 2006 improved $22.2 million over the first half of 2005.

As of June 30, PRA maintained cash and cash equivalents of $86.1 million and no significant long-term debt.

"New business awards increased more than 25% under our new business development model, which has been in place for only two quarters," president and chief executive officer Pat Donnelly said in a news release.

"We anticipate a steady flow of proposals over the balance of the year with an emphasis on penetrating the large pharma sector."

Management increased its 2006 service revenue guidance to a range of $300 million to $320 million and anticipates full-year fully diluted earnings per share in the range of $1.15 to $1.26.

PRA is a clinical development organization based in Reston, Va.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.